Compound with René

Compound with René

Deep Dives

Deep Dive: Novo Nordisk ($NVO)

Novo Nordisk’s -58% Stock Crash: A Bet on the Future of Healthcare at a Reasonable Price?

René Sellmann's avatar
René Sellmann
Apr 17, 2025

Novo Nordisk has long stood out among global healthcare companies, particularly in the diabetes care market. From groundbreaking treatments to a robust pipeline of new therapies, the company has been a magnet for investor attention.

Yet, more recently, the stock of Novo Nordisk has been struggling, facing its biggest drawdown in its history as a public company.

Understanding whether Novo Nordisk is a solid long-term investment goes far beyond simply recognizing it as a leader in diabetes.

In this blog post, we’ll explore how Novo Nordisk operates at its core, where its true competitive advantages lie, how its leadership steers the ship, what the numbers say about its valuation, and, of course, the risks any savvy investor should keep in mind.

Thanks for reading Quality Investing with René Sellmann! Subscribe for free to receive new posts and support my work.

What Does Novo Nordisk Actually Do? Inside the Global Healthcare Giant

When you think of companies shaping the future of healthcare, Novo Nordisk deserves a front-row seat. This Danish pharmaceutical giant has carved out a dominant niche in diabetes and obesity care, with blockbuster drugs like Ozempic and Wegovy fueling explosive growth.

In 2024, the company reported a jaw-dropping 22% sales increase to DKK 290.4 billion (~$41 billion), with operating profits hitting DKK 140 billion (~$18 billion).

Its global diabetes market share now stands at one-third, and its GLP-1 franchise—led by the revolutionary semaglutide—commands roughly two-thirds of the worldwide GLP-1 market.

(Source: Novo Nordisk Q3 Presentation)

Disclaimer: The analysis presented in this blog may be flawed and/or critical information may have been overlooked. The content provided should be considered an educational resource and should not be construed as individualized investment advice, nor as a recommendation to buy or sell specific securities. I may own some of the securities discussed. The stocks, funds, and assets discussed are examples only and may not be appropriate for your individual circumstances. It is the responsibility of the reader to do their own due diligence before investing in any index fund, ETF, asset, or stock mentioned or before making any sell decisions. Also double-check if the comments made are accurate. You should always consult with a financial advisor before purchasing a specific stock and making decisions regarding your portfolio.”

What Makes Novo Nordisk’s Engine Roar?

A Portfolio That Redefines Chronic Care

At its core, Novo Nordisk is a specialist in metabolic diseases, with a laser focus on diabetes and obesity treatments. Its product lineup is a masterclass in innovation, anchored by insulin analogues and GLP-1 receptor agonists.

Household names like Ozempic (a weekly injectable for type-2 diabetes), Rybelsus (the first oral semaglutide), and Wegovy (a higher-dose semaglutide for obesity) have redefined their categories. Semaglutide, the star molecule, delivers unmatched blood sugar control and weight loss—Wegovy’s clinical trials showed an astonishing ~15% body weight reduction, setting a new benchmark for obesity care. These drugs aren’t just effective; they’re convenient, with options like once-weekly injections or daily pills that make adherence easier for patients.

(Source: Novo Nordisk Q3 Presentation)

Beyond its current heavyweights, Novo Nordisk’s pipeline is brimming with promise. Candidates like CagriSema (combining semaglutide with cagrilintide for even greater weight loss), once-weekly insulin icodec, and amycretin (an oral GLP-1/amylin co-agonist) highlight a relentless innovation culture.

“In obesity, we completed the first phase 3 trial of CagriSema, currently in development for the treatment of obesity or overweight and type 2 diabetes. After 68 weeks, if all people adhered to treatment, CagriSema demonstrated a statistically significant weight loss of 22.7% vs 2.3% with placebo alone. This is among the highest weight reductions yet seen in a phase 3a programme for a GLP-1 combination therapy. We intend to further explore the weight loss potential of CagriSema in an additional study.“

The company is also exploring triple-agonist therapies targeting GLP-1, GIP, and glucagon receptors, ensuring it stays ahead of the curve.

While diabetes and obesity are the core focus, Novo also maintains smaller franchises in rare bleeding disorders (like NovoSeven for hemophilia) and growth hormone therapy, though these play supporting roles.

The result is a focused, high-impact portfolio that sets the gold standard in efficacy, commands premium pricing, and drives blockbuster sales—Ozempic and Wegovy alone raked in DKK 120 billion (~$17 billion) and DKK 58 billion (~$8 billion) in 2024.

Share

A Business Built for Resilience and Scale

The rest of this post is FREE to read. I only ask that you subscribe, which costs nothing and can be undone with a single click whenever you like.

The wall also helps keep my writing from being freely scraped by AI crawlers, so I hope you understand the small extra step.

In return, you get every deep dive, earnings review, and process piece I publish, straight to your inbox.

Subscribe for free to continue reading

Enter your email and get every post from Compound with René.
Already have an account? Sign in
© 2026 René Sellmann · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.